Life-Threatening Complications Continue to Challenge Venous Access.

technology - thrombosis.jpg

Thrombosis

Blood platelets react to the catheter material, forming blood clots that impede catheter flow and can lead to serious conditions like deep vein thrombosis and pulmonary embolism.

technology - infection.jpg

Infection

Bacteria are introduced during catheter insertion or accumulate in thrombosed sections of the catheter wall, leading to bloodstream infections.

technology - phlebitis.jpg

Phlebitis

Catheters can damage the vein wall during insertion, leading to swelling and pain.

Our Novel Catheter Material Could Change Everything.

*Data on file at Access Vascular. Reduction of thrombosis accumulation was evaluated using in vitro and in vivo models.

*Data on file at Access Vascular. Reduction of thrombosis accumulation was evaluated using in vitro and in vivo models.

technology - evidence.jpg

Read Our Evidence

In Vitro and In Vivo Assessments of Novel Catheter Material

Testing includes an FDA-recognized blood flow loop test conducted by Thrombodine Inc and placement of HydroPICC devices in ovine models for 14 or 28 days. PowerPICC and BioFlo are registered trademarks of Bard Access Systems and AngioDynamics, respectively.

A Suite of Venous Access Devices

Access Vascular plans to develop a variety of venous catheters leveraging our novel hydrogel material that address the $3 billion global venous access market

suite of devices.png